Compare Biocon Ltd with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs FRESENIUS KABI ONCO. - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON FRESENIUS KABI ONCO. BIOCON /
FRESENIUS KABI ONCO.
 
P/E (TTM) x 17.1 22.1 77.1% View Chart
P/BV x 2.6 3.1 84.8% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 BIOCON    FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    BIOCON
Mar-18
FRESENIUS KABI ONCO.
Mar-13
BIOCON /
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,188176 675.0%   
Low Rs30579 388.5%   
Sales per share (Unadj.) Rs68.737.7 182.4%  
Earnings per share (Unadj.) Rs7.65.1 148.3%  
Cash flow per share (Unadj.) Rs14.06.7 207.8%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs86.342.5 203.0%  
Shares outstanding (eoy) m600.00158.23 379.2%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.93.4 321.7%   
Avg P/E ratio x98.925.0 395.7%  
P/CF ratio (eoy) x53.418.9 282.3%  
Price / Book Value ratio x8.63.0 289.0%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m447,90020,135 2,224.5%   
No. of employees `0006.11.2 533.8%   
Total wages/salary Rs m9,311703 1,324.1%   
Avg. sales/employee Rs Th6,705.85,176.2 129.6%   
Avg. wages/employee Rs Th1,514.2610.4 248.1%   
Avg. net profit/employee Rs Th736.9699.6 105.3%   
INCOME DATA
Net Sales Rs m41,2345,963 691.5%  
Other income Rs m2,06218 11,455.6%   
Total revenues Rs m43,2965,981 723.9%   
Gross profit Rs m8,2911,430 579.7%  
Depreciation Rs m3,851258 1,493.2%   
Interest Rs m615-26 -2,365.4%   
Profit before tax Rs m5,8871,216 484.0%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,569342 458.5%   
Profit after tax Rs m4,531806 562.2%  
Gross profit margin %20.124.0 83.8%  
Effective tax rate %26.728.1 94.7%   
Net profit margin %11.013.5 81.3%  
BALANCE SHEET DATA
Current assets Rs m41,4865,102 813.2%   
Current liabilities Rs m21,4132,385 897.7%   
Net working cap to sales %48.745.6 106.9%  
Current ratio x1.92.1 90.6%  
Inventory Days Days64150 42.6%  
Debtors Days Days94113 83.1%  
Net fixed assets Rs m50,6615,148 984.1%   
Share capital Rs m3,000158 1,896.3%   
"Free" reserves Rs m48,8086,556 744.5%   
Net worth Rs m51,8086,732 769.6%   
Long term debt Rs m17,898952 1,879.6%   
Total assets Rs m99,89710,388 961.7%  
Interest coverage x10.6-45.8 -23.1%   
Debt to equity ratio x0.30.1 244.2%  
Sales to assets ratio x0.40.6 71.9%   
Return on assets %5.27.5 68.6%  
Return on equity %8.712.0 73.1%  
Return on capital %9.614.6 66.0%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m12,0585,298 227.6%   
Fx outflow Rs m7,3481,772 414.6%   
Net fx Rs m4,7103,525 133.6%   
CASH FLOW
From Operations Rs m6,6211,274 519.7%  
From Investments Rs m-6,840-1,204 568.0%  
From Financial Activity Rs m-2,397-196 1,222.3%  
Net Cashflow Rs m-2,612-126 2,068.1%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 81.0 25.4%  
Indian inst/Mut Fund % 8.4 0.3 2,800.0%  
FIIs % 10.7 9.6 111.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 9.1 218.7%  
Shareholders   109,995 42,599 258.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  WYETH LTD  ABBOTT INDIA  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Sep 20, 2019 (Close)

TRACK BIOCON

BIOCON - PIRAMAL ENTERPRISES COMPARISON

COMPARE BIOCON WITH

MARKET STATS